Follow-On Biologics Bill Could Be Shaped By Waxman/Dingell Fight For House Commerce Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Chairmanship would give Waxman more leverage to place regulatory flexibility into the biosimilars approval pathway.